Skip to main content

Who prescribes donepezil or memantine for dementia? Not Geriatricians from the Bronx...


by: Eric Widera (@ewidera)

There are two main drug classes use to treat Alzheimer's disease, cholinesterase inhibitors (ChEIs) and the NMDA-antagonist memantine. Both have shown statistically significant improvements in outcomes for patients with AD, but the clinical significance of these benefits is marginal at best.   Furthermore, these benefits vary with disease severity, with ChEIs showing benefit from mild to servere dementia, and memantine showing benefit only in moderate to severe disease.

So how closely does clinical practice mirror the evidence behind these drugs?   A new study in JAGS suggests that your chances of being started on these drugs is about 50/50, and has less to do with FDA approved indications, and more to do with who you see and where you live.

The Study

The authors used a national sample of Medicare beneficiaries enrolled in Medicare Part D from 2008 to 2010 and evaluated the frequency of ChEI’s and mematine prescription fills in people with a diagnosis of any type of dementia.  They compared individuals with similar disease severity based on a proxy of whether the participant lived in residential care. Because the measure may be imperfect in its correlation with dementia severity, drug use according to whether the participant died within a year of index diagnosis was also reported.  Information on visits to a neurologist, psychiatrist, or geriatrician in the 2 months before and after the date of the initial diagnosis was captured as an indicator of specialty involvement.

The Results

1. About half (56%) of all people with a dementia diagnosis receive either cholinesterase-inhibitors or memantine within a year of the index diagnosis.

2. There is no difference between use of ChEI or memantine related to the study’s proxy measure for dementia severity.   Furthermore, about half (45%) of those patients with dementia who died within 1 year of their index diagnosis were on one of these agents.

3. Factors not directly related to dementia, such as race and region of residence, influence treatment rates ChEI or memantine.    Turns out Bronx, NY, has the lowest rates of using them!

4. The type of clinician involved in care may independently influence whether a person is treated with ChEI or memantine.   Neurologists and psychiatrists are more likely and geriatricians less likely to prescribe ChEI’s and memantine than when primary care manages alone.


The Take Home

Apparently, if you don't want to be put on cholinesterase inhibitors (ChEIs) or memantine, live in the Bronx and visit with a local geriatrician.  


Comments

Wonder Doc said…
So true. As a Geriatrician, I see these meds prescribed all the time for any stage or type of dementia. I usually explain to patients who see me for consultation that 'doctors like to fix things and you can't fix dementia; so they feel like they're doing something if they give you a prescription.' While, the education against the meds takes longer than most physicians have, I don't find that the limited benefits of the drugs are often clearly reviewed with or understood by these patients.

Popular posts from this blog

The Future of Palliative Care: A Podcast with Diane Meier

There are few names more closely associated with palliative care than Diane Meier.  She is an international leader of palliative care, a MacArthur "genius" awardee, and amongst many other leadership roles, the CEO of the Center to Advance Palliative Care (CAPC).  We were lucky enough to snag Diane for our podcast to talk about everything we always wanted to ask her, including:
What keeps her up at night?Does palliative care need a national strategy and if so why and what would it look like?The history of CAPC and the leadership centersAdvice that she has for graduating fellows who want to continue to move palliative care forward as they start their new careersWhat she imagines palliative care will look like in 10 or 15 years?What is the biggest threat facing palliative care? So take a listen and if you want to dive a little deeper, here are two articles that we discussed during the podcast:
A National Strategy For Palliative Care. Health Affairs 2017Palliative Care Leadership…

Advance Care Planning before Major Surgery: A Podcast with Vicky Tang

This week's podcast is all about the intersection of geriatrics, palliative care, advanced care planning and surgery with our guest Dr. Vicky Tang.  Vicky is an assistant professor and researcher here at UCSF.  We talk about her local and national efforts focused on this intersection, including:
Her JAMA Surgery article that showed 3 out of 4 older adults undergoing high risk surgery had no advance care planning (ACP) documentation. Prehab clinics and how ACP fits into these clinicsThe Geriatric Surgery Verification Quality Improvement Program whose goal is to set the standards for geriatric surgical care including ACP discussions prior to surgeryHow frailty fits in and how to assess it (including this paper from JAGS on the value of the chair raise test) So take a listen and check out some of those links.  For those who want to take a deeper dive into how GeriPal and surgery fit together, check out these other podcasts: Zara Cooper on Trauma Surgery, Geriatrics, and Palliative Car…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …